Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday. Blood serum analysis of 30 pediatric participants who received a booster dose in a study showed a 36-fold increase in Omicron neutralizing antibodies, the drugmakers said. Neutralizing antibodies against the original version of the virus for which the vaccine was designed rose six-fold following the booster shot.